Duration of immunotherapy in patients with advanced lung adenocarcinoma with negative driver genes: case report and literature review
In conclusion, whether the drug can be disco ntinued in advance after immune checkpoint inhibitor (ICI) therapy has been effective remains a concern, and at present there is no final conclusion in the medical profession. However, the results of this study indicate that early withdrawal of immunotherapy due to adverse reactions might also benef it patients with advanced lung adenocarcinoma with negative driver genes who achieve an early response to immunotherapy.
Source: Thoracic Cancer - Category: Cancer & Oncology Authors: Qinge Shan,
Haiyong Wang,
Xiao Han,
Jun Guo,
Zhehai Wang Tags: CASE REPORT Source Type: research
More News: Adenocarcinoma | Cancer | Cancer & Oncology | Genetics | Immunotherapy | Lung Cancer | Non-Small Cell Lung Cancer | Skin | Study | Toxicology